IDEX Corp beats Q3 estimates on strong demand for health and science products

IDEX

29/10/2025 11:31

Oct 29 (Reuters) - Industrial equipment maker IDEX Corp IEX.N on Wednesday posted a stronger-than-expected profit and revenue for the third quarter, helped by a protracted recovery in its health and science product lines.

Sales in the health and science technology segment rose 22% from a year earlier, as customers continued to restock after working through the large inventories built up during the COVID-19 pandemic.

The unit supplies components used in clinical diagnostics and drug discovery, as well as in food processing and cosmetic manufacturing.

IDEX narrowed its 2025 adjusted profit to between $7.86 and $7.91, compared with a prior view of $7.85 to $7.95.

Excluding items, the company's quarterly earnings stood at $2.03 per share, higher than Wall Street expectations of $1.93, according to data compiled by LSEG.

Its total revenue rose 10% to nearly $879 million for the quarter ended September 30, while analysts on average were expecting revenue of $862 million.

 (Reporting by Aishwarya Jain in Bengaluru; Editing by Shailesh Kuber)

 ((Aishwarya.Jain@thomsonreuters.com;))